Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
Rachel N. Grisham
No relevant relationships to disclose
Evis Sala
No relevant relationships to disclose
Qin Zhou
No relevant relationships to disclose
Alexia Iasonos
No relevant relationships to disclose
Deborah DeLair
No relevant relationships to disclose
Gopa Iyer
No relevant relationships to disclose
David Michael Hyman
No relevant relationships to disclose
David R. Spriggs
No relevant relationships to disclose
Carol Aghajanian
No relevant relationships to disclose